Your browser doesn't support javascript.
loading
Dynamic changes in nocturnal heart rate predict short-term cardiovascular events in patients using the wearable cardioverter-defibrillator: from the WEARIT-France cohort study.
Garcia, Rodrigue; Warming, Peder Emil; Narayanan, Kumar; Defaye, Pascal; Guedon-Moreau, Laurence; Blangy, Hugues; Piot, Olivier; Leclercq, Christophe; Marijon, Eloi.
  • Garcia R; Department of Cardiology, University Hospital of Poitiers, 86021 Poitiers, France.
  • Warming PE; Centre d'Investigation Clinique CIC1402, CHU Poitiers, 86000, Poitiers, France.
  • Narayanan K; Department of Cardiology, Copenhagen University Hospital, Rigshospitalet, Denmark.
  • Defaye P; Department of Cardiology, Medicover Hospitals, Hyderabad, Telangana 500081, India.
  • Guedon-Moreau L; Université Paris Cité, Inserm, PARCC, F-75015 Paris, France.
  • Blangy H; Department of Cardiology, University Hospital Grenoble Alpes, Grenoble 38043, France.
  • Piot O; Heart and Lung Institute, University Hospital of Lille, Lille 59000, France.
  • Leclercq C; Department of Cardiology, University Hospital of Nancy, Vandoeuvre-Lès-Nancy 54500, France.
  • Marijon E; Department of Cardiology, Cardiology Center of Nord, Saint Denis 93200, France.
Europace ; 25(5)2023 05 19.
Article en En | MEDLINE | ID: mdl-37021342
ABSTRACT

AIMS:

While elevated resting heart rate measured at a single point of time has been associated with cardiovascular outcomes, utility of continuous monitoring of nocturnal heart rate (NHR) has never been evaluated. We hypothesized that dynamic NHR changes may predict, at short term, impending cardiovascular events in patients equipped with a wearable cardioverter-defibrillator (WCD). METHODS AND

RESULTS:

The WEARIT-France prospective cohort study enrolled heart failure patients with WCD between 2014 and 2018. Night-time was defined as midnight to 7 a.m. NHR initial trajectories were classified into four categories based on mean NHR in the first week (High/Low) and NHR evolution over the second week (Up/Down) of WCD use. The primary endpoint was a composite of cardiovascular death and heart failure hospitalization. A total of 1013 [61 (interquartile range, IQR 53-68) years, 16% women, left ventricular ejection fraction 26% (IQR 22-30)] were included. During a median WCD wear duration of 68 (IQR 44-90) days, 58 patients (6%) experienced 69 events. After considering potential confounders, High-Up NHR trajectory was significantly associated with the primary endpoint compared to Low-Down [adjusted hazard ratio (HR) 6.08, 95% confidence interval (CI) 2.56-14.45, P < 0.001]. Additionally, a rise of >5 bpm in weekly average NHR from the preceding week was associated with 2.5 higher composite event risk (HR 2.51, 95% CI 1.22-5.18, P = 0.012) as well as total mortality (HR 11.21, 95% CI 3.55-35.37, P < 0.001) and cardiovascular hospitalization (HR 2.70, 95% CI 1.51-4.82, P < 0.001).

CONCLUSION:

Dynamic monitoring of NHR may allow timely identification of impending cardiovascular events, with the potential for 'pre-emptive' action. REGISTRATION NUMBER Clinical Trials.gov Identifier NCT03319160.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Dispositivos Electrónicos Vestibles / Insuficiencia Cardíaca Tipo de estudio: Diagnostic_studies / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Female / Humans / Male Idioma: En Año: 2023 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Dispositivos Electrónicos Vestibles / Insuficiencia Cardíaca Tipo de estudio: Diagnostic_studies / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Female / Humans / Male Idioma: En Año: 2023 Tipo del documento: Article